In Silico prediction of cytochrome P450-drug interaction: QSARs for CYP3a4 and CYP2C9

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Nembri, Serena ^a   Grisoni, Francesca ^a   Consonni, Viviana ^a   Todeschini, Roberto ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

ADMET; CYP2C9; CYP3A4; Cytochrome P450; In silico; QSAR

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 2C9 INHIBITOR; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; PROTEIN BINDING;

ALGORITHM; ARTICLE; CALIBRATION; COMPUTER MODEL; DRUG INTERACTION; DRUG SCREENING; DRUG TARGETING; HYDROGEN BOND; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; HUMAN; METABOLISM;

ANIMALS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2C9 INHIBITORS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; HUMANS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84973527678     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060914     Document Type: Article

References (71)

1. Munro, A.W.; Girvan, H.M.; Mason, A.E.; Dunford, A.J.; McLean, K.J. What makes a P450 tick? Trends Biochem. Sci. 2013, 38, 140-150. [CrossRef] [PubMed]
2. Yan, Z.; Caldwell, G.W. Metabolism Profiling, and Cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 2001, 1, 403-425. [PubMed]
3. Singh, D.; Kashyap, A.; Pandey, R.V.; Saini, K.S. Novel advances in cytochrome P450 research. Drug Discov. Today 2011, 16, 793-799. [CrossRef] [PubMed]
4. Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 2013, 138, 103-141. [CrossRef] [PubMed]
5. Pb, W. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin. Liver Dis. 1990, 10, 235-250.
6. Gonzalez, F.J.; Gelboin, H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 1994, 26, 165-183. [CrossRef] [PubMed]
7. Gonzalez, F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat. Res. Mol. Mech. Mutagen. 2005, 569, 101-110. [CrossRef] [PubMed]
8. Langowski, J.; Long, A. Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Deliv. Rev. 2002, 54, 407-415. [CrossRef]
9. Kirton, S.B.; Baxter, C.A.; Sutcliffe, M.J. Comparative modelling of cytochromes P450. Adv. Drug Deliv. Rev. 2002, 54, 385-406. [CrossRef]
10. Todeschini, R.; Consonni, V. Molecular Descriptors for Chemoinformatics; John Wiley & Sons: Hoboken, NJ, USA, 2009; Volume 41.
11. Li, H.; Sun, J.; Fan, X.; Sui, X.; Zhang, L.; Wang, Y.; He, Z. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction. J. Comput. Aided Mol. Des. 2008, 22, 843-855. [CrossRef] [PubMed]
12. Yap, C.W.; Chen, Y.Z. Prediction of Cytochrome P450 3A4, 2D6, and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model. 2005, 45, 982-992. [CrossRef] [PubMed]
13. Rostkowski, M.; Spjuth, O.; Rydberg, P. WhichCyp: Prediction of cytochromes P450 inhibition. Bioinformatics 2013, 29, 2051-2052. [CrossRef] [PubMed]
14. Pan, X.; Chao, L.; Qu, S.; Huang, S.; Yang, L.; Mei, H. An improved large-scale prediction model of CYP1A2 inhibitors by using combined fragment descriptors. RSC Adv. 2015, 5, 84232-84237. [CrossRef]
15. Sun, H.; Veith, H.; Xia, M.; Austin, C.P.; Huang, R. Predictive models for cytochrome P450 isozymes based on quantitative high throughput screening data. J. Chem. Inf. Model. 2011, 51, 2474-2481. [CrossRef] [PubMed]
16. Jensen, B.F.; Vind, C.; Brockhoff, P.B.; Refsgaard, H.H.F. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using gaussian kernel weighted k-Nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J. Med. Chem. 2007, 50, 501-511. [CrossRef] [PubMed]
17. Balakin, K.V.; Ekins, S.; Bugrim, A.; Ivanenkov, Y.A.; Korolev, D.; Nikolsky, Y.V.; Skorenko, A.V.; Ivashchenko, A.A.; Savchuk, N.P.; Nikolskaya, T. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab. Dispos. 2004, 32, 1183-1189. [CrossRef] [PubMed]
18. Veith, H.; Southall, N.; Huang, R.; James, T.; Fayne, D.; Artemenko, N.; Shen, M.; Inglese, J.; Austin, C.P.; Lloyd, D.G. et al. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat. Biotechnol. 2009, 27, 1050-1055. [CrossRef] [PubMed]
19. NCBI The PubChem Project. Available online: http://pubchem.ncbi.nlm.nih.gov/(accessed on1 March 2016).
20. Talete srl. Dragon (Software for Molecular Descriptor Calculation). Version 6.0.
21. Available online: http://www.talete.mi.it/(accessed on 8 June 2016).
22. Rogers, D.; Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 2010, 50, 742-754. [CrossRef] [PubMed]
23. Kode srl. Dragon (Software for Molecular Descriptor Calculation), Version 7.0. Pisa, Italy, 2016.
24. Goldberg, D.E.; Holland, J.H. Genetic algorithms and machine learning. Mach. Learn. 1988, 3, 95-99. [CrossRef]
25. Grisoni, F.; Cassotti, M.; Todeschini, R. Reshaped sequential replacement for variable selection in QSPR: Comparison with other reference methods. J. Chemom. 2014, 28, 249-259. [CrossRef]
26. Breiman, L.; Friedman, J.; Stone, C.J.; Olshen, R.A. Classification and Regression Trees; CRC Press: Boca Raton, FL, USA, 1984.
27. Kowalski, B.R.; Bender, C.F. K-Nearest Neighbor Classification Rule (pattern recognition) applied to nuclear magnetic resonance spectral interpretation. Anal. Chem. 1972, 44, 1405-1411. [CrossRef]
28. Todeschini, R.; Ballabio, D.; Cassotti, M.; Consonni, V. N3 and BNN: Two new similarity based classification methods in comparison with other classifiers. J. Chem. Inf. Model. 2015, 55, 2365-2374. [CrossRef] [PubMed]
29. McLachlan, G.J. Discriminant Analysis and Statistical Pattern Recognition; Wiley: Hoboken, NJ, USA, 1992.
30. Ståhle, L.; Wold, S. Partial least squares analysis with cross-validation for the two-class problem: A Monte Carlo study. J. Chemom. 1987, 1, 185-196. [CrossRef]
31. Sahigara, F.; Mansouri, K.; Ballabio, D.; Mauri, A.; Consonni, V.; Todeschini, R. Comparison of different approaches to define the applicability domain of QSAR models. Molecules 2012, 17, 4791-4810. [CrossRef] [PubMed]
32. Jolliffe, I. Principal component analysis. In Wiley StatsRef: Statistics Reference Online; John Wiley & Sons, Ltd.: Boca Raton, FL, USA, 2014.
33. Smith, D.A.; Jones, B.C.; Walker, D.K. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 1996, 16, 243-266. [CrossRef]
34. De Montellano, P.R.O. Cytochrome P450: Structure, Mechanism, and Biochemistry; Springer Science & Business Media: Berlin, Germany; Heidelberg, Germany, 2005.
35. Guengerich, F.P. Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J. Biochem. Mol. Toxicol. 2007, 21, 163-168. [CrossRef] [PubMed]
36. Guengerich, F.P. Oxidation of halogenated compounds by cytochrome P-450, peroxidases, and model metalloporphyrins. J. Biol. Chem. 1989, 264, 17198-17205.
37. Meunier, B.; Visser, S.P.D. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 2004, 104, 3947-3980. [CrossRef] [PubMed]
38. Mutschler, E.; Derendorf, H. Drug Actions: Basic Principles and Theraputic Aspects; CRC Press: Boca Raton, FL, USA, 1995.
39. Guroff, G.; Daly, J.W.; Jerina, D.M.; Renson, J.; Witkop, B.; Udenfriend, S. Hydroxylation-induced migration: The NIH shift. Recent experiments reveal an unexpected and general result of enzymatic hydroxylation of aromatic compounds. Science 1967, 157, 1524-1530. [CrossRef] [PubMed]
40. Magnuson, V.R.; Harriss, D.K.; Basak, S.C. Topological indices based on neighborhood symmetry: Chemical and biological applications. Chem. Appl. Topol. Graph Theory 1983, 178-191.
41. Raunio, H.; Kuusisto, M.; Juvonen, R.O.; Pentikäinen, O.T. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Front. Pharmacol. 2015, 6. [CrossRef] [PubMed]
42. Jiao, D.; Golubkov, P.A.; Darden, T.A.; Ren, P. Calculation of protein-ligand binding free energy by using a polarizable potential. Proc. Natl. Acad. Sci. USA 2008, 105, 6290-6295. [CrossRef] [PubMed]
43. Stauffer, D.A.; Karlin, A. Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. Biochemistry 1994, 33, 6840-6849. [CrossRef] [PubMed]
44. Butina, D. Performance of Kier-hall E-state descriptors in quantitative structure activity relationship (QSAR) studies of multifunctional molecules. Molecules 2004, 9, 1004-1009. [CrossRef] [PubMed]
45. Gunes, A.; Coskun, U.; Boruban, C.; Gunel, N.; Babaoglu, M.O.; Sencan, O.; Bozkurt, A.; Rane, A.; Hassan, M.; Zengil, H. et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin. Pharmacol. Toxicol. 2006, 98, 197-200. [CrossRef] [PubMed]
46. Gilbar, P.J.; Brodribb, T.R. Phenytoin and fluorouracil interaction. Ann. Pharmacother. 2001, 35, 1367-1370. [CrossRef] [PubMed]
47. Brown, M.C. An adverse interaction between warfarin and 5-fluorouracil: A case report and review of the literature. Chemotherapy 1999, 45, 392-395. [CrossRef] [PubMed]
48. Stiborová, M.; Bieler, C.A.; Wiessler, M.; Frei, E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 2001, 62, 1675-1684. [CrossRef]
49. Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 1997, 19, 255-263. [CrossRef] [PubMed]
50. Roy, K.; Saha, A. QSPR with TAU indices: Water solubility of diverse functional acyclic compounds. Intern. Electron. J. Mol. Des. 2003, 2, 475-491.
51. Moriguchi, I.; Hirono, S.; Liu, Q.; Nakagome, I.; Matsushita, Y. Simple method of calculating octanol/water partition coefficient. Chem. Pharm. Bull. 1992, 40, 127-130. [CrossRef]
52. Lewis, D.F.V.; Jacobs, M.N.; Dickins, M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov. Today 2004, 9, 530-537. [CrossRef]
53. Hansch, C.; Zhang, L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab. Rev. 1993, 25, 1-48. [CrossRef] [PubMed]
54. Al-Gailany, K.A.S.; Houston, J.B.; Bridges, J.W. The role of substrate lipophilicity in determining type 1 microsomal P450 binding characteristics. Biochem. Pharmacol. 1978, 27, 783-788. [CrossRef]
55. Ramos-Nino, M.E.; Clifford, M.N.; Adams, M.R. Quantitative structure activity relationship for the effect of benzoic acids, cinnamic acids and benzaldehydes on Listeria monocytogenes. J. Appl. Bacteriol. 1996, 80, 303-310. [CrossRef] [PubMed]
56. Consonni, V.; Todeschini, R. New spectral indices for molecule description. MATCH 2008, 1, 2.
57. Geary, R.C. The contiguity ratio and statistical mapping. Inc. Stat. 1954, 5, 115-146. [CrossRef]
58. Carhart, R.E.; Smith, D.H.; Venkataraghavan, R. Atom pairs as molecular features in structure-activity studies: Definition and applications. J. Chem. Inf. Comput. Sci. 1985, 25, 64-73. [CrossRef]
59. Grisoni, F.; Consonni, V.; Vighi, M.; Villa, S.; Todeschini, R. Investigating the mechanisms of bioconcentration through QSAR classification trees. Environ. Int. 2016, 88, 198-205. [CrossRef] [PubMed]
60. Cassotti, M.; Consonni, V.; Mauri, A.; Ballabio, D. Validation and extension of a similarity-based approach for prediction of acute aquatic toxicity towards Daphnia magna. SAR QSAR Environ. Res. 2014, 25, 1013-1036. [CrossRef] [PubMed]
61. Mansouri, K.; Abdelaziz, A.; Rybacka, A.; Roncaglioni, A.; Tropsha, A.; Varnek, A.; Zakharov, A.; Worth, A.; Richard, A.M.; Grulke, C.M. et al. CERAPP: Collaborative estrogen receptor activity prediction project. Environ. Health Perspect. 2016. [CrossRef] [PubMed]
62. Gissi, A.; Nicolotti, O.; Carotti, A.; Gadaleta, D.; Lombardo, A.; Benfenati, E. Integration of QSAR models for bioconcentration suitable for REACH. Sci. Total Environ. 2013, 456-457, 325-332. [CrossRef] [PubMed]
63. Fp, G. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol. 1996, 43, 7-35.
64. Walters, W.P.; Stahl, M.T.; Murcko, M.A. Virtual screening—An overview. Drug Discov. Today 1998, 3, 160-178. [CrossRef]
65. James, C.A.; Weininger, D.; Delany, J. Daylight Theory Manual; Daylight Chemical Information Systems, Inc.: Aliso Viejo, CA, USA, 1995; 3951p.
66. Leardi, R.; Lupiáñez González, A. Genetic algorithms applied to feature selection in PLS regression: How and when to use them. Chemom. Intell. Lab. Syst. 1998, 41, 195-207. [CrossRef]
67. Cassotti, M.; Grisoni, F. Variable selection methods: An introduction. Available online: http://www. moleculardescriptors.eu (accessed on 2 February 2016).
68. Sahigara, F.; Ballabio, D.; Todeschini, R.; Consonni, V. Defining a novel k-Nearest neighbours approach to assess the applicability domain of a QSAR model for reliable predictions. J. Cheminform. 2013, 5, 27. [CrossRef] [PubMed]
69. Berthold, M.R.; Cebron, N.; Dill, F.; Gabriel, T.R.; Kötter, T.; Meinl, T.; Ohl, P.; Sieb, C.; Thiel, K.; Wiswedel, B. KNIME: The konstanz information miner. In Data Analysis, Machine Learning and Applications; Preisach, C., Burkhardt, P.D.H., Schmidt-Thieme, P.D.L., Decker, P.D.R., Eds.; Studies in Classification, Data Analysis, and Knowledge Organization; Springer: Berlin, Germany; Heidelberg, Germany, 2008; pp. 319-326.
70. MATLAB, 2015. R2015a; The MathWorks Inc.: Natick, MA, USA, 2015.
71. Milano Chemometrics and QSAR Research Group. Available online: http://michem.disat.unimib.it/chm/ download/datasets.htm (accessed on 3 March 2016).